Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
CPRT has spent the past month shedding 12% to $26.37, and the story since the last note six days ago is a sharpening tension: options traders have swung to their most bullish positioning of the year while an index rebalance clock quietly ticks in the background.
The options market is the standout this week. Calls now dominate put activity by a wider margin than at almost any point in the past year. The put/call ratio has dropped to 0.47, nearly three standard deviations below its 20-day average of 0.54, and that z-score of -2.75 is the most bullish reading in the dataset. The 52-week low on the PCR is 0.20, so there is room to go further, but the move from last week's 0.54 to this week's 0.47 is sharp. This is not defensive repositioning ahead of earnings: it is call-buying into a falling stock, six weeks before the November 19 print.
Short interest has continued the retreat described in last week's note, and that trend has accelerated. The short position fell another 12% over the past week to 3.03% of the free float, around 29.4 million shares, down from 43 million in early September. That is a 32% decline in a single month. Borrow remains essentially free at 0.38%, and availability is uncapped, so the exit is not being forced. Shorts are choosing to leave. The ORTEX short score has also eased, slipping from 35.8 a fortnight ago to 34.1, consistent with a position that is unwinding rather than building. Positioning, taken together, looks bullish in structure even as the price chart is not.
The Street is cautiously constructive but not unified. Analyst moves since early September show a split: JPMorgan upgraded to Overweight with a $40 target after the September earnings drop, and BNP Paribas raised its target to $43 while reiterating Outperform as recently as September 28. HSBC moved the other way, cutting to Hold with a $36 target in mid-September. Barclays remains the outlier, sitting at Underweight with a $25 target that sits below the current price. The mean target across the group is $39, implying roughly 48% upside from $26.37, a gap that reflects genuine disagreement about the recovery timeline rather than consensus optimism. The PE has compressed to 15.3x over the past month, down from around 18x, and price-to-book has fallen to 2.1x. The bull case centres on global ASP growth of 5.6% in the most recent quarter and the rising share of international buyers. The bear case focuses on depressed unit volume and slipping gross transaction values in adjacent auction markets.
The more mechanical risk sits in the index calendar. ORTEX puts the probability of Copart being deleted from the Nasdaq-100 at the December 2026 Annual Review at 62%. The ranking date is November 30, the announcement December 11, and the effective date December 21. The stock needs to close above $29.11 to stay above the exit line; it is currently 10.4% below that threshold. If deletion is confirmed, index trackers would need to sell an estimated $2.1 billion of CPRT stock, equivalent to 7.7 days of normal trading volume. Among 19 similar past deletions, 79% of stocks moved in the expected direction (lower), with median decline from announcement to effective of 3.5% and trade-day volume running at 7.4 times normal. That is not a prediction of what happens here, but the mechanical selling pressure would be real, and the November 30 ranking snapshot is now six weeks away.
The alt-data picture adds one further data point worth noting. Copart posted its largest quarterly buyback on record in the April quarter, spending $1.41 billion, the highest reading since the series began in 2009. That capital allocation choice, buying back shares aggressively into weakness, runs directly against the index deletion risk: a smaller float and lower market cap make the exit line harder to clear, not easier. Retail attention, as measured by Wikipedia page views against the stock's own 90-day history, is running 1.4 standard deviations below average, suggesting the options call-buying is not driven by fresh retail interest.
What to watch next is whether the stock can recover above the $29.11 threshold before the November 30 ranking snapshot, and whether the call-buying in options reflects genuine institutional conviction or simply short-term hedging being unwound ahead of earnings on November 19.
See the live data behind this article on ORTEX.
Open CPRT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
